The very latest presentation from the last 24 hours is at the...

The very latest presentation from the last 24 hours is at the Annual Needham Healthcare Conference and this coincides with the name change, so is interesting to listen to (unfortunately the associated slideshow is not included, but it's stuff holders already know):

It summarises the 3 main products in the following order of importance:

1/ the Vapendavir trials - for treating those moderate to severe Asthmatics, COPD, pediatric and others prone to increased respiratory risk after contracting HRV (common cold)
Patti does mention in passing "proof of activity in reducing signs and symptoms of the common cold".  This general comment was good to hear in passing - a hint of the possibilities even though it is meant only for those with moderate to severe respiratory complications.

2/ the recent FDA approved fast-tracked BTA585 trials - for RSV, particularly in Pediatric and other at-risk population.

3/ BTA074 - for treatment of genital warts

The first two products are looking at trial results second half of this year.

Reference is made to the fact that there is over $50m in the bank - enough to see these 3 trials through with sufficient capital left over.

Register for the audio at:
http://www.wsw.com/webcast/needham76